The study included 58 patients with HCV infection and prior history of treated hepatocelullar carcinoma. They all also underwent anti-HCV treatment with all-oral direct acting antivirals in four hospitals.
Here are three key insights:
1. After a median follow-up of 5.7 months, three patients died and 16 developed radiologic tumor recurrence.
2. The pattern of recurrence was intrahepatic growth, new intrahepatic lesion and infiltrative ill-defined hepatocellular carcinoma and/or extra-hepatic lesions in three patients.
3. Though the study is based in a very small cohort of patients, the results should be taken as a note of caution, the investigators note.
More articles on GI/endoscopy:
Olympus launches enhanced GI benchmarking product, HCSC issues coverage for Torax Medical’s LINX system & more — 5 GI company key notes
Mercy Health names Dr. Anton Decker chief clinical officer: 3 things to know
Gastroenterologist to know: Dr. Gary Matusow of Gastroenterology Group & Endoscopy Center of South Jersey
